Literature DB >> 29191053

Diagnosis and Management of Conjunctivitis for the Dermatologist.

Melinda Gooderham1,2,3, Julian McDonald4, Kim Papp3,5.   

Abstract

Atopic dermatitis is a chronic, sometimes relapsing inflammatory skin condition that presents with pruritus and characteristic skin manifestations. Conjunctivitis is a common ocular comorbidity affecting almost half of patients with the risk increasing with atopic dermatitis severity. Recent targeted biologic therapies that successfully treat atopic skin disease, including dupilumab, which blocks interleukin (IL)-4 and IL-13, as well as agents that block IL-13 alone, have been associated with an increased rate of conjunctivitis in clinical trials. Because conjunctivitis commonly occurs in patients with atopic dermatitis and as the treatment with targeted biologic agents may increase the risk or severity of conjunctivitis, it is important that dermatologists recognize symptoms, appreciate treatment options, and know when referral to an ophthalmologist is appropriate.

Entities:  

Keywords:  atopic dermatitis; conjunctivitis; dupilumab; interleukin-13; interleukin-4

Mesh:

Substances:

Year:  2017        PMID: 29191053     DOI: 10.1177/1203475417743233

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  4 in total

1.  Dupilumab-associated ulcerative keratitis.

Authors:  Matthew M Wilson; Philipp K Roberts; Mark Daniell
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

Review 2.  A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.

Authors:  Gaurav Agnihotri; Katherine Shi; Peter A Lio
Journal:  Drugs R D       Date:  2019-12

3.  Conjunctivitis in dupilumab clinical trials.

Authors:  B Akinlade; E Guttman-Yassky; M de Bruin-Weller; E L Simpson; A Blauvelt; M J Cork; E Prens; P Asbell; E Akpek; J Corren; C Bachert; I Hirano; J Weyne; A Korotzer; Z Chen; T Hultsch; X Zhu; J D Davis; L Mannent; J D Hamilton; A Teper; H Staudinger; E Rizova; G Pirozzi; N M H Graham; B Shumel; M Ardeleanu; A Wollenberg
Journal:  Br J Dermatol       Date:  2019-05-07       Impact factor: 9.302

Review 4.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.